---
title: How I diagnose and treat systemic mastocytosis with an associated hematologic
  neoplasm
date: '2025-01-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39808818/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250115170812&v=2.18.0.post9+e462414
source: Blood
description: Over the last decade significant advances have been made by honing in
  on the diagnostic evaluation and the significance of molecular profiles in patients
  with systemic mastocytosis (SM), non-advanced and advanced.This is reflected in
  the 2022 iterations of the World Health Organization Edition 5 and International
  Consensus Criteria classifications.The impact of targeted KIT inhibitor therapies
  on patients treated within global trials has demonstrated significant improvements
  in the prognosis ...
disable_comments: true
---
Over the last decade significant advances have been made by honing in on the diagnostic evaluation and the significance of molecular profiles in patients with systemic mastocytosis (SM), non-advanced and advanced.This is reflected in the 2022 iterations of the World Health Organization Edition 5 and International Consensus Criteria classifications.The impact of targeted KIT inhibitor therapies on patients treated within global trials has demonstrated significant improvements in the prognosis ...